These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18927997)

  • 21. Prevnar(tm): a pneumococcal conjugate vaccine for infants and young children.
    Brown A
    Issues Emerg Health Technol; 2001 Feb; (14):1-6. PubMed ID: 11902222
    [No Abstract]   [Full Text] [Related]  

  • 22. Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: a Belgian consensus report.
    Peetermans WE; Van de Vyver N; Van Laethem Y; Van Damme P; Thiry N; Trefois P; Geerts P; Schetgen M; Peleman R; Swennen B; Verhaegen J
    Acta Clin Belg; 2005; 60(6):329-37. PubMed ID: 16502593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
    Jiang Y; Gauthier A; Keeping S; Carroll S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):901-11. PubMed ID: 25186657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pneumococcal vaccination in adults: does it really work?
    Pitsiou GG; Kioumis IP
    Respir Med; 2011 Dec; 105(12):1776-83. PubMed ID: 21816596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverage.
    Watson M; Bayley K; Bell JM; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Roche P; Smith HV; Stewart MG; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2003; 27(4):478-87. PubMed ID: 15508501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreasing invasive pneumococcal disease in the elderly: a state-level analysis.
    McBean AM; Jung K; Hebert PL
    Vaccine; 2006 Jul; 24(27-28):5609-14. PubMed ID: 16725240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients.
    Forstner C; Plefka S; Tobudic S; Winkler HM; Burgmann K; Burgmann H
    Vaccine; 2012 Aug; 30(37):5449-52. PubMed ID: 22749594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Serious invasive pneumococcal disease in young children: the importance of vaccination].
    Haveman LM; Geelen SP; Sanders EA; Wolfs TF
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1917-20. PubMed ID: 12404904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
    Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
    Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nasopharyngeal carriage rate of Streptococcus pneumoniae in children with sickle cell disease before and after the introduction of heptavalent pneumococcal conjugate vaccine.
    Alexander E; Telfer P; Rashid H; Ali KA; Booy R
    J Infect Public Health; 2008; 1(1):40-4. PubMed ID: 20701844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
    Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA;
    Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumococcal vaccines WHO position paper--2012.
    Wkly Epidemiol Rec; 2012 Apr; 87(14):129-44. PubMed ID: 24340399
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention.
    Bridy-Pappas AE; Margolis MB; Center KJ; Isaacman DJ
    Pharmacotherapy; 2005 Sep; 25(9):1193-212. PubMed ID: 16164394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Neuzil KM; Whitney CG; Starkovich P; Dunstan M; Yu O; Nelson JC; Feikin DR; Shay DK; Baggs J; Carste B; Nahm MH; Carlone G
    Vaccine; 2005 May; 23(28):3697-703. PubMed ID: 15882530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
    Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
    Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.
    Klugman KP; Madhi SA; Huebner RE; Kohberger R; Mbelle N; Pierce N;
    N Engl J Med; 2003 Oct; 349(14):1341-8. PubMed ID: 14523142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine.
    Adam HJ; Karlowsky JA; Nichol KA; Gilmour MW; Hoban DJ; Embree J; Zhanel GG
    Microb Drug Resist; 2012 Apr; 18(2):176-82. PubMed ID: 22204595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.